ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

6 links0 made here, not in the record7 judgments1 judge (the rules as one: Rule based)0 record changes seen
Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05516914A Phase Ib/II ClinicalTrial of LBL-007 CombinedWith Tislelizumab in theTreatment of MalignantTumorsNanjing Leads Biolabs Co.,LtdPhase 1/Phase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionDRUGSAlcestobartEntry “LBL-007 Injection”, read by ou…›As of now · Rule based · TestedTestedTislelizumabEntry “Tislelizumab Injection”, read …›As of now · Rule based · TestedTestedCisplatinEntry “Cisplatin Injection”, read by …›As of now · Rule based · BackgroundBackgroundGemcitabineEntry “Gemcitabine Hydrochloride for …›As of now · Rule based · BackgroundBackgroundDocetaxelEntry “Docetaxel injection”, read by …›As of now · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Neoplasms

From the registry record2 judgments on this link
Kind of condition link, from the registry to what was judged
RegistryNeoplasms, as filedthe registry files the study under it
→judged
Main condition (R9)

All judgments on this study

WhenLinkJudgeDecisionState
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
As of nowNeoplasmsRule based · main-condition ruleMain conditionCurrent
As of nowAlcestobartRule based · role ruleTestedCurrent
As of nowTislelizumabRule based · role ruleTestedCurrent
As of nowCisplatinRule based · role ruleBackgroundCurrent
As of nowGemcitabineRule based · role ruleBackgroundCurrent
As of nowDocetaxelRule based · role ruleBackgroundCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.